Key Highlights
- Prestige Consumer Healthcare (NYSE: PBH) finalized a $95 million term loan to partially fund its acquisition of LaCorium Health Australia.
- The company priced $400 million in senior unsecured notes due 2034 to support the transaction and related expenses.
- The LaCorium acquisition closed recently, after obtaining the necessary regulatory and financing approvals.
- Prestige Consumer Healthcare amended its existing credit agreement to access the additional $95 million in term loans.
Deal Completion Announced
Prestige Consumer Healthcare (NYSE: PBH) has closed its acquisition of LaCorium Health Australia and related entities, marking a strategic expansion into the Australian healthcare market. The transaction was finalized after securing the required financing and regulatory clearances. The deal underscores the company’s focus on growing its international portfolio.
Financing Structure Revealed
To fund the acquisition, Prestige Consumer Healthcare secured a $95 million term loan under an amended credit agreement. The additional borrowing capacity was approved by lenders including Citibank, Barclays, and Morgan Stanley, allowing the company to draw the full $95 million on the closing date. The funds were earmarked for the LaCorium purchase and associated transaction costs.
Senior Notes Offering Priced
Prestige Consumer Healthcare announced a private placement of $400 million in senior unsecured notes with a maturity horizon extending into the mid‑2030s. The notes were priced shortly after the acquisition closed, providing further liquidity to support the company’s growth initiatives. Proceeds will be used to refinance existing debt and fund general corporate purposes.
Credit Agreement Amendment
The company amended its term loan credit agreement to permit the additional $95 million borrowing. The amendment was executed with Citibank as administrative agent and included participation from key lenders. This adjustment reflects Prestige Consumer Healthcare’s efforts to optimize its capital structure ahead of the LaCorium integration.
Acquisition Target Details
LaCorium Health Australia and its affiliated entities, including Stantail Trading and Laderma Holdings, operate in the Australian healthcare sector. The acquisition aligns with Prestige Consumer Healthcare’s strategy to diversify its product offerings and geographic reach. No financial terms beyond the financing arrangements were disclosed.
Regulatory Filing Requirements
Prestige Consumer Healthcare intends to include the amended credit agreement in its forthcoming Form 10‑Q filing covering the most recent reporting period. This filing will provide investors with full details of the transaction and financing terms, ensuring compliance with securities regulations and transparency for shareholders.
Market Implications
The acquisition and financing moves signal Prestige Consumer Healthcare’s confidence in its growth trajectory. The $400 million notes offering and $95 million term loan position the company to pursue further strategic opportunities. Investors will monitor the integration of LaCorium and its impact on earnings.
FAQs
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.


_11_19_2026_12_58_12_592184.jpg)



Please wait processing your request...